MICROBIOLOGY SUSCEPTIBLITY REPORTING
exp date isn't null, but text field is
Reporting of antibiotic susceptibility from microbiology laboratories is changing in line with EUCAST recommendations. From June 2021, you will see more antibiotics reported as I as well as the more familiar S and R. The definitions of these are listed below
S |
Susceptible at standard dose |
I |
Susceptible, increased exposure (= increased dose) |
R |
Resistant even with increased exposure/dose |
Agents reported as “I” are still appropriate treatment options when given at the correct (higher) dose. These higher doses are listed in the table below.
If in doubt or antibiotic dose not listed below please discuss with clinical microbiologist.
Drug |
Increased Dose |
Benzylpenicillin |
1.2g to 2.4g 4-6 hourly |
Temocillin IV |
2g 8 hourly |
Piperacillin/tazobactam IV |
4.5g 6 hourly |
Ceftazidime IV |
2g 8 hourly |
Aztreonam IV |
2g 6 hourly |
Co-trimoxazole IV/Oral |
1440mg 12 hourly |
Amoxicillin Oral |
1g 8 hourly |
Co-amoxiclav Oral |
Co-amoxiclav 625mg 8 hourly |
Levofloxacin IV/Oral |
500mg 12 hourly |
Ciprofloxacin IV |
400mg 8 hourly |
Ciprofloxacin Oral |
750mg 12 hourly |
Please note these doses are applicable to dosing in adults with normal renal and hepatic function. In impaired hepatic/renal function please adjust accordingly/discuss with pharmacist.
For information on dose changes for children, please see the advice from Scottish Antimicrobial Prescribing Group, Paediatric Stewardship Working Group
Aminoglycoside sensitivity reporting has changed in line with EUCAST recommendations. This does not affect clinical practice, provided patients are improving on therapy.